RxDoctor Payments Data

Charles Mitgang, MD

Internal Medicine · Rockville Centre, NYNPI 1114923315

Payments from drug & device makers

$26,442in general payments, 2019–2025

Across 1,292 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • GSK$2K
  • Pfizer$2K
  • Lilly USA, LLC$1K
  • plus $13K from 54 others

What the payments were for

  • Food & beverage$26,328100%
  • Education$1140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)230$3,711
Novo Nordisk125$2,404
AstraZeneca89$2,267
GSK107$2,111
Pfizer108$2,036
Lilly USA, LLC62$1,132
Amgen43$927
Boehringer Ingelheim43$901
Sanofi29$868
Merck49$820
Johnson & Johnson39$801
Nestle Healthcare Nutrition Inc.31$748
Amarin Pharma, Inc.43$735
Esperion Therapeutics, Inc.22$640
Sanofi-aventis U.S. LLC22$611
E.r. Squibb & Sons, L.L.C.19$510
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)19$476
Novartis23$465
Exact Sciences13$340
Abbott7$301
Daiichi Sankyo Inc.12$276
Takeda Pharmaceuticals U.S.A., Inc.11$248
Teva Pharmaceuticals USA, Inc.11$244
Kowa Pharmaceuticals America, Inc.14$211
Scilex Pharmaceuticals Inc.9$198
Almatica Pharma LLC8$179
Astellas Pharma US Inc9$178
Phathom Pharmaceuticals, Inc.6$176
Sumitomo Pharma America, Inc.5$147
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$126
Verona Pharma, Inc.1$125
Arbor Pharmaceuticals, Inc.7$120
Lundbeck LLC6$118
Ironwood Pharmaceuticals, Inc5$113
Renalytix AI, Inc.5$108
Axsome Therapeutics, Inc.3$87
Eisai Inc.4$82
Corcept Therapeutics4$71
Alnylam Pharmaceuticals Inc.3$69
Bausch Health US, LLC3$64
Sun Pharmaceutical Industries Inc.3$53
Alfasigma USA, Inc.3$48
Agios Pharmaceuticals, Inc.2$45
Amneal Pharmaceuticals LLC2$44
Bayer2$37
Linus Health, Inc.1$35
Hologic Sales And Service, LLC1$27
Smith+Nephew1$26
Seqirus USA Inc1$25
Boston Scientific1$25
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$25
Genentech USA, Inc.1$25
Dexcom, Inc.1$24
Idorsia Pharmaceuticals US Inc1$24
Jazz Pharmaceuticals Inc.1$24
Paratek Pharmaceuticals, Inc.1$23
EUSA Pharma (US) LLC1$22
Recordati_rare_diseases_inc.1$22
Corium, LLC1$22
Biohaven Pharmaceutical Holding Company Ltd.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,442 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$650,488
Medicare patients
1,262
Services billed
7,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$187,014
FarxigaDapagliflozin Propanediol118$145,192
EliquisApixaban102$130,364
XareltoRivaroxaban72$92,560
JanuviaSitagliptin Phosphate52$73,358
JardianceEmpagliflozin34$58,086
LinzessLinaclotide34$40,263
JanumetSitagliptin Phos/Metformin Hcl26$34,663
RybelsusSemaglutide11$23,684
Rosuvastatin Calcium1,184$21,920
TopamaxTopiramate14$21,772
EntrestoSacubitril/Valsartan14$21,706
Repatha SureclickEvolocumab15$19,712
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$18,853
Spiriva RespimatTiotropium Bromide25$17,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,404$210,697115 claims
AstraZenecaFarxiga, Symbicort$2,267$150,404131 claims
PfizerEliquis$2,036$130,364102 claims
MerckJanuvia, Janumet$820$108,02078 claims
Johnson & JohnsonXarelto$801$92,56072 claims
Boehringer IngelheimJardiance, Spiriva Respimat$901$75,81559 claims
AbbVieLinzess, Synthroid$3,711$50,344155 claims
GSKTrelegy Ellipta, Breo Ellipta$2,111$24,30824 claims
NovartisEntresto$465$21,70614 claims
Astellas Pharma US IncMyrbetriq$178$10,98713 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$44$9,132466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rockville Centre

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →